These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 17126073)

  • 1. Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker.
    Berry C; Murphy NF; De Vito G; Galloway S; Seed A; Fisher C; Sattar N; Vallance P; Hillis WS; McMurray J
    Eur J Heart Fail; 2007 Apr; 9(4):429-34. PubMed ID: 17126073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    Weir RA; McMurray JJ; Puu M; Solomon SD; Olofsson B; Granger CB; Yusuf S; Michelson EL; Swedberg K; Pfeffer MA;
    Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anti-aldosterone therapy in severe heart failure].
    van Guldener C; Donker AJ
    Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1724-6. PubMed ID: 10494316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure.
    McMurray JJ; Pitt B; Latini R; Maggioni AP; Solomon SD; Keefe DL; Ford J; Verma A; Lewsey J;
    Circ Heart Fail; 2008 May; 1(1):17-24. PubMed ID: 19808266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Adaptation of guidelines for the treatment of chronic heart failure in a specialized heart failure clinic].
    Pölzl G; Gouya G; Hügel H; Frick M; Ulmer H; Pachinger O
    Wien Klin Wochenschr; 2002 Oct; 114(19-20):833-9. PubMed ID: 12503474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heart failure.
    McKelvie R
    Clin Evid; 2004 Jun; (11):122-48. PubMed ID: 15652002
    [No Abstract]   [Full Text] [Related]  

  • 7. Heart failure.
    McKelvie R
    Clin Evid; 2004 Dec; (12):115-43. PubMed ID: 15865633
    [No Abstract]   [Full Text] [Related]  

  • 8. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker.
    Chrysostomou A; Pedagogos E; MacGregor L; Becker GJ
    Clin J Am Soc Nephrol; 2006 Mar; 1(2):256-62. PubMed ID: 17699214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure.
    Lenzen MJ; Boersma E; Reimer WJ; Balk AH; Komajda M; Swedberg K; Follath F; Jimenez-Navarro M; Simoons ML; Cleland JG
    Eur Heart J; 2005 Dec; 26(24):2706-13. PubMed ID: 16183692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High prevalence of microalbuminuria in chronic heart failure patients.
    van de Wal RM; Asselbergs FW; Plokker HW; Smilde TD; Lok D; van Veldhuisen DJ; van Gilst WH; Voors AA
    J Card Fail; 2005 Oct; 11(8):602-6. PubMed ID: 16230263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of aldosterone antagonism in heart failure: pharmacotherapeutic options].
    Diercks GF; Overdiek JW; van Veldhuisen DJ
    Ned Tijdschr Geneeskd; 2001 Feb; 145(5):204-8. PubMed ID: 11219145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to guidelines for patients hospitalized with heart failure: a nationwide survey.
    Jotkowitz AB; Porath A; Shotan A; Mittelman M; Grossman E; Zimlichman R; Lewis BS; Caspi A; Gottlieb S; Garty M;
    Isr Med Assoc J; 2006 Dec; 8(12):875-9. PubMed ID: 17214110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of neurohormonal modulators in heart failure with relatively preserved systolic function.
    Rapp JA; Gheorghiade M
    Heart Fail Clin; 2005 Apr; 1(1):77-93. PubMed ID: 17386836
    [No Abstract]   [Full Text] [Related]  

  • 14. An approach to heart failure and diabetes mellitus.
    Fonarow GC
    Am J Cardiol; 2005 Aug; 96(4A):47E-52E. PubMed ID: 16098844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
    van de Wal RM; Plokker HW; Lok DJ; Boomsma F; van der Horst FA; van Veldhuisen DJ; van Gilst WH; Voors AA
    Int J Cardiol; 2006 Jan; 106(3):367-72. PubMed ID: 16337046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure).
    van Veldhuisen DJ; Cohen-Solal A; Böhm M; Anker SD; Babalis D; Roughton M; Coats AJ; Poole-Wilson PA; Flather MD;
    J Am Coll Cardiol; 2009 Jun; 53(23):2150-8. PubMed ID: 19497441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment.
    Macdonald JE; Kennedy N; Struthers AD
    Heart; 2004 Jul; 90(7):765-70. PubMed ID: 15201246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J; Fraccarollo D
    Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heart failure: recent advances in prevention and treatment.
    Fonarow GC
    Rev Cardiovasc Med; 2000; 1(1):25-33, 54. PubMed ID: 12457149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
    Dieterich HA; Wendt C; Saborowski F
    Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.